We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Review · May 20, 2021

MK-6482 as a Potential Treatment for VHL Disease-Associated Clear Cell RCC

Expert Opinion on Investigational Drugs

 

Additional Info

Disclosure statements are available on the authors' profiles:

Expert Opinion on Investigational Drugs
MK-6482 as a Potential Treatment for von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
Expert Opin Investig Drugs 2021 May 04;[EPub Ahead of Print], E Hasanov, E Jonasch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.